ClinicalTrials.gg
CompletedNCT00035594Updated May 9, 2013

Pegfilgrastim as Support to Advanced Breast Cancer Patients Receiving Chemotherapy

A Phase 3 interventional study of pegfilgrastim in Neutropenia, sponsored by Amgen. Completed. Per ClinicalTrials.gov, last updated 2013-05-09.

Sponsored by Amgen · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
928
Allocation
Randomized
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 33 studies testing pegfilgrastim in Neutropenia — none open to participants now, none under way, none of them phase 3. pegfilgrastim · Neutropenia.

Enrollment
Largest of 28
928 · median 121
Started
2002
with 4 others
Phase 3
11 of 33
none open now
Registered
3rd of 33
by date
Lead sponsor
10 of 33
Amgen

Among the 33 studies testing pegfilgrastim in Neutropenia, this one has the largest enrollment of the 28 interventional ones that give a count, is one of 5 that started in 2002, is one of 11 in phase 3, and was the 3rd registered.

Neutropenia

316 studies on the registry are indexed under Neutropenia; 42 are open to participants now.

Browse Neutropenia studies →

Open to participants now

None of the 33 studies testing pegfilgrastim in Neutropenia is open now. The open studies under Neutropenia, anywhere →

About pegfilgrastim

pegfilgrastim: first FDA approval 2002 (NEULASTA), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 24 Neutropenia studies recruiting now, 12 (50%) set no upper age limit and 12 (50%) stop at 75 or younger; 11 take children under 18; 1 takes healthy volunteers.

This study: no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 33 studies testing pegfilgrastim in Neutropenia as a file.
02

Study summary

Physicians are conducting a clinical trial for patients with advanced breast cancer. Breast cancer can be treated with chemotherapy which can affect the bone marrow, where blood cells are produced. Neutrophils are a type of white blood cells that fight infection and are produced in the bone marrow. If the neutrophil count becomes low due to chemotherapy, a potentially serious condition called neutropenia occurs. Neutropenia is serious because it can affect the body's ability to protect against many types of infections. Pegfilgrastim is an investigational drug being evaluated for its potential ability to increase the number of neutrophils. The purpose of this study is to determine the safety and effectiveness of pegfilgrastim in preventing neutropenia following chemotherapy in patients with advanced breast cancer.

03

Conditions studied

  • Neutropenia

Keywords

  • Breast cancer
  • Neutropenia
  • Chemotherapy
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Accepts healthy volunteers
No

Eligibility criteria

  • Advanced breast cancer
  • 18 years of age or older
  • Patients who will be receiving Taxotere (docetaxel) chemotherapy
05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
928 participants

Study arms

  • Placebo comparator
    Placebo

    Breast cancer patients receiving docetaxel chemotherapy and placebo.

    Drug: pegfilgrastim

  • Experimental
    Pegfilgrastim

    Breast cancer patients receiving docetaxel chemotherapy and pegfilgrastim.

    Drug: pegfilgrastim

Interventions

  • Growth factor (GCSF) administered to promote neutrophil development post-chemotherapy.

06

What researchers measure

Primary outcomes

  1. Proportion of subjects developing febrile neutropenia

    Time frame: Through 4 cycles

Secondary outcomes

  1. Incidence of hospitalization and IV antiinfective use associated with FN; also chemotherapy planned dose on time

    Time frame: Through 4 cycles

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Vogel CL, Wojtukiewicz MZ, Carroll RR, Tjulandin SA, Barajas-Figueroa LJ, Wiens BL, Neumann TA, Schwartzberg LS. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol. 2005 Feb 20;23(6):1178-84. doi: 10.1200/JCO.2005.09.102. PubMed 15718314 ↗
  • Lyman GH, Reiner M, Morrow PK, Crawford J. The effect of filgrastim or pegfilgrastim on survival outcomes of patients with cancer receiving myelosuppressive chemotherapy. Ann Oncol. 2015 Jul;26(7):1452-8. doi: 10.1093/annonc/mdv174. Epub 2015 Apr 7. PubMed 25851633 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2002, a primary completion of Feb 2004 and a completion of Jun 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2002
First posted
May 6, 2002
Start
Feb 2002
Primary completionActual
Feb 2004
CompletionActual
Jun 2004
Last update
May 9, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 9, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00035594
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
May 6, 2002
Start date
Feb 2002
Primary completion
Feb 2004
Completion
Jun 2004
Last update
May 9, 2013

Study contacts

MD
study director · Amgen
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegfilgrastim

Start the discussion